Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Posttransfusion hepatitis in Toronto, Canada.

S V Feinman1, B Berris, S Bojarski

  • 1Department of Medicine, Mount Sinai Hospital, University of Toronto, Ontario, Canada.

Gastroenterology
|August 1, 1988
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world effectiveness of peginterferon α-2b plus ribavirin in a Canadian cohort of treatment-naïve chronic hepatitis C patients with genotypes 2 or 3: results of the PoWer and RediPEN studies.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2016
Same author

Viral hepatitis: new aspects of an old disease.

Canadian family physician Medecin de famille canadien·2011
Same author

Investigation of fatigue.

Canadian family physician Medecin de famille canadien·2011
Same author

Frequency of hepatitis B antigen.

Canadian Medical Association journal·2010
Same author

Telangiectases in scleroderma.

Canadian Medical Association journal·2010
Same author

Peginterferon alfa-2a in patients with chronic hepatitis C.

The New England journal of medicine·2000
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterology·2026
Same journal

Reply to "Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterology·2026
Same journal

Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy.

Gastroenterology·2026
Same journal

A High-Risk Impaction: To Scope or to Stent First?

Gastroenterology·2026
Same journal

Epithelial FOXP3 Orchestrates O-Glycosylated IL6 Secretion to Drive Pancreatic Fibrocarcinogenesis.

Gastroenterology·2026
Same journal

Reply.

Gastroenterology·2026
See all related articles

A significant 9.2% of patients developed non A, non B hepatitis after blood transfusions. Many progressed to chronic hepatitis, highlighting transfusion risks for liver disease.

Area of Science:

  • Hepatology
  • Transfusion Medicine
  • Infectious Diseases

Background:

  • Posttransfusion hepatitis remains a concern despite screening.
  • Non A, non B hepatitis poses a significant risk to transfusion recipients.

Purpose of the Study:

  • To determine the incidence of acute and chronic non A, non B hepatitis following blood transfusions.
  • To identify risk factors associated with posttransfusion hepatitis development and progression.

Main Methods:

  • Prospective follow-up of 576 patients receiving volunteer blood transfusions for 6 months.
  • Monitoring for development of acute and chronic hepatitis.
  • Analysis of patient demographics, transfusion details, and clinical factors.

Main Results:

Related Experiment Videos

  • 9.2% of patients developed acute posttransfusion non A, non B hepatitis, with incubation periods typically 2-8 weeks.
  • 36% of acute cases progressed to chronic hepatitis.
  • Higher alanine aminotransferase levels during acute hepatitis correlated with progression to chronic disease.

Conclusions:

  • Transfusion-associated non A, non B hepatitis occurs frequently, even with screened blood.
  • A substantial proportion of acute cases progress to chronic liver disease.
  • This highlights the need for continued vigilance and improved strategies to prevent transfusion-transmitted hepatitis.